[Hiring] Director, Global Value and Health Economics and Outcomes Research @Jazz Pharmaceuticals

Role Description

The Director, Global Value and HEOR is a strategic and execution-oriented leadership role accountable for the global and US payer evidence strategy across marketed assets in Jazz’ neurology portfolio. This role is responsible for maximizing brand potential, defending value, securing expanded access, and driving evidence generation across the post-launch lifecycle—including label expansions (sNDA/sBLA), new formulations, line extensions, and competitive market shifts.

Operating across both broad commercial disease areas and high-uncertainty rare diseases, the Director serves as the strategic evidence engine substantiating the evolving product value story developed by the Market Access team. As a vital stakeholder in the Integrated Evidence Generation Plan (IEGP) governance and brand strategy forums, this role translates commercial, access, and policy priorities into methodologically sound evidence generation plans and tangible deliverables—including updated global core economic models, real-world observational studies, patient registries, Global Value Dossiers (GVDs), and US AMCP dossiers.

The Director carries a dual global and regional leadership mandate: serving as the dedicated US HEOR lead while collaborating seamlessly with the EU/INT HEOR team.

Qualifications

• Master’s degree (MSc, MS, MPH) or PhD in Health Economics, Outcomes Research, Pharmacoeconomics, or a closely related quantitative field.
• Minimum of 7–10 years of experience in HEOR, Global Value, or Health Economics within the biopharmaceutical industry or a top-tier HEOR consulting firm.
• Experience with oncology assets preferred.
• Deep understanding of US payers and population health decision makers including Oncology pathways.
• Strong peer-reviewed publication record in health economics and outcomes research.

Requirements

• Extensive experience in designing and executing post-marketing HEOR strategies, real-world comparative effectiveness studies, and evidence roadmaps supporting label expansions (sNDA/sBLA), line extensions, and value defense against competitors.
• Comprehensive working knowledge of the US managed care landscape and global HTA environments.
• Proven technical expertise in building, adapting, and validating economic models utilizing mature real-world and clinical trial data.
• Proven track record in collaborating with US Market Access, Pricing/Contracting, and Payer Field Teams.
• Demonstrated understanding of the unique post-launch evidence challenges in rare diseases.
• Working knowledge of major US and global healthcare databases and advanced epidemiological methods for comparative research.
• Demonstrated ability to work collegially with dedicated regional HEOR teams.
• Ability to seamlessly balance macro-level evidence strategy with hands-on execution of complex technical deliverables.
• Exceptional verbal, written, and presentation skills.

Benefits

• Medical, dental, and vision insurance.
• 401k retirement savings plan.
• Flexible paid vacation.
• Discretionary annual cash bonus or incentive compensation.
• Discretionary equity grants.

Company Description

Jazz Pharmaceuticals is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide.